Literature DB >> 18249130

Risk factors for occult nodal metastasis in clinical T1N0 lung cancer: a negative impact on survival.

Nirmal K Veeramachaneni1, Richard J Battafarano, Bryan F Meyers, Jennifer Bell Zoole, G Alexander Patterson.   

Abstract

BACKGROUND: The application of CT imaging has increased the identification of patients with clinical T1N0 (cT1N0) lung cancer. The optimal management strategy for these early stage lung cancers remains unclear. We analyzed the impact of occult nodal metastasis on cT1N0 lung cancer patients.
METHODS: We studied patients with cT1N0 lung cancer enrolled in our database from January 1995 to December 2002. Preoperative staging was confirmed by review of CT and PET scan studies. Pathology specimens were reviewed. Multivariate analysis was performed to determine the risk of occult nodal involvement. Kaplan-Meier method was applied to analyze survival.
RESULTS: Two hundred and ninety-seven patients with cT1N0 disease were identified. Fifty-eight percent of patients were pathological T1N0. Overall, 15% of patients had occult nodal metastasis. Logistic regression analysis demonstrated a three-fold increase in the risk of having pathologic stage II or stage III disease with every 1.0 cm increase in tumor size (odds ratio 3.2; 95% CI: 2.3-4.6). Multivariate analysis demonstrated tumor size to be a significant predictor of nodal metastasis (adjusted odds ratio 3.5; 95% CI: 2.4-5.1). Median survival was different between pathological stage I (96.3 months), stage II (41.4 months), and stage III (36.1 months) disease (p=0.002).
CONCLUSION: Clinical T1N0 tumors are often understaged. The risk of occult nodal disease increases with tumor size, and this occult disease negatively impacts survival. Because of the limitations of clinical staging, we believe that lobectomy and lymph node analysis should be offered to cT1N0 lung cancer patients to provide accurate staging and to optimize multimodality adjuvant treatment of lung cancer.

Entities:  

Mesh:

Year:  2008        PMID: 18249130     DOI: 10.1016/j.ejcts.2007.12.015

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  17 in total

1.  Tumor Spread Through Air Spaces Is a Predictor of Occult Lymph Node Metastasis in Clinical Stage IA Lung Adenocarcinoma.

Authors:  Raj G Vaghjiani; Yusuke Takahashi; Takashi Eguchi; Shaohua Lu; Koji Kameda; Zachary Tano; Jordan Dozier; Kay See Tan; David R Jones; William D Travis; Prasad S Adusumilli
Journal:  J Thorac Oncol       Date:  2020-01-30       Impact factor: 15.609

2.  [Long-term survival of personalized surgical treatment of locally advanced non-small cell lung cancer based on molecular staging].

Authors:  Qinghua Zhou; Yingkang Shi; Jun Chen; Bin Liu; Yun Wang; Daxing Zhu; Hong-Tao Zhang; Peng Xu; Youling Gong; Gang Chen; Sen Wei; Xiaoming Qiu; Zhongxi Niu; Xiaofeng Chen; Zhe Lei; Liang Duan; Zhu Wu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-02

3.  Negative predictive value of positron emission tomography and computed tomography for stage T1-2N0 non-small-cell lung cancer: a meta-analysis.

Authors:  Jingbo Wang; Kathy Welch; Luhua Wang; Feng-Ming Spring Kong
Journal:  Clin Lung Cancer       Date:  2011-11-03       Impact factor: 4.785

4.  Prevalence of Occult Peribronchial N1 Nodal Metastasis in Peripheral Clinical N0 Small (≤2 cm) Non-Small Cell Lung Cancer.

Authors:  Eric M Robinson; Ilkka K Ilonen; Kay See Tan; Andrew J Plodkowski; Matthew Bott; Manjit S Bains; Prasad S Adusumilli; Bernard J Park; Valerie W Rusch; David R Jones; James Huang
Journal:  Ann Thorac Surg       Date:  2019-08-31       Impact factor: 4.330

5.  Relapse in resected lung cancer revisited: does intensified follow up really matter? A prospective study.

Authors:  Dragan Subotic; Dragan Mandaric; Gordana Radosavljevic; Jelena Stojsic; Milan Gajic; Maja Ercegovac
Journal:  World J Surg Oncol       Date:  2009-11-12       Impact factor: 2.754

6.  Metabolic parameters using ¹⁸F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma.

Authors:  Do-Hoon Kim; Bong-Il Song; Chae Moon Hong; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-03       Impact factor: 9.236

7.  Risk Factors for Predicting Occult Lymph Node Metastasis in Patients with Clinical Stage I Non-small Cell Lung Cancer Staged by Integrated Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.

Authors:  Kaoru Kaseda; Keisuke Asakura; Akio Kazama; Yukihiko Ozawa
Journal:  World J Surg       Date:  2016-12       Impact factor: 3.352

8.  The number of resected lymph nodes (nLNs) combined with tumor size as a prognostic factor in patients with pathologic N0 and Nx non-small cell lung cancer.

Authors:  Miaomiao Yang; Hongxin Cao; Xi Guo; Tiehong Zhang; Pingping Hu; Jiajun Du; Qi Liu
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

9.  Preoperative clinical and tumor genomic features associated with pathologic lymph node metastasis in clinical stage I and II lung adenocarcinoma.

Authors:  Raul Caso; James G Connolly; Jian Zhou; Kay See Tan; James J Choi; Gregory D Jones; Brooke Mastrogiacomo; Francisco Sanchez-Vega; Bastien Nguyen; Gaetano Rocco; Daniela Molena; Smita Sihag; Prasad S Adusumilli; Matthew J Bott; David R Jones
Journal:  NPJ Precis Oncol       Date:  2021-07-21

10.  Identification of false-negative and false-positive diagnoses of lymph node metastases in non-small cell lung cancer patients staged by integrated (18F-)fluorodeoxyglucose-positron emission tomography/computed tomography: A retrospective cohort study.

Authors:  Kaoru Kaseda; Ken-Ichi Watanabe; Keisuke Asakura; Akio Kazama; Yukihiko Ozawa
Journal:  Thorac Cancer       Date:  2016-05-05       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.